Cerenome Announced Interim Data From Its Ongoing ReSPECT-LM Study Of Repeated Intraventricular Dosing Of REYOBIQ; No Dose-Limiting Toxicities Or Adverse Events Leading To Treatment Discontinuation Have Been Reported

Benzinga
Open on Benzinga